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Background/Purpose 
The Hospital Anxiety and Depression Scale (HADs) is a generic measure of psychological status 
comprising anxiety and depression subscales. The aim of this study was to assess the psychometric 
properties of HADs in psoriatic arthritis (PsA), to calibrate the scale, and to provide interval-level 
scale for use in parametric analyses when required. 
Methods 
We used HADS data from patients with PsA recruited in PRESTA trial. [1] The data was subjected 
to Rasch analysis to determine fit to the Rasch model (implying construct validity 
and unidimensionality), reliability and targeting in subjects with PsA. 
Results 
The number of evaluable subjects was 740 at baseline, 701 at week 12, and 653 at week 24. Both the 
anxiety subscale and the depression subscale satisfied the expectation of the Rasch model (table 1). 
The overall scale was shown to fit the Rasch model (item-by-severity interaction Chi-Square = 15.878, 
p = 0.601) and had excellent reliability (person separation index = 0.888). Validity and reliability of 
HADS were confirmed at baseline and both follow-up visits. 
Figure 1 presents person location relative to all items (logarithmically transformed scores) along the 
same scale (logits). The top plot ƌĞƉƌĞƐĞŶƚŝŶŐ  ?ƉĞƌƐŽŶƐƐĞǀĞƌŝƚǇ ? ?ƚŚŽƐĞǁŝƚŚŚŝŐŚĞƌƐĐŽƌĞƐ  ?ŝŵƉĂŝƌĞd 
psychological status) on the right of the scale and those with lower scores (better psychological 
status) on the left. The bottom plot presents relative  ?ĚŝĨĨŝĐƵůƚǇ ?ŽĨƚŚĞŝƚĞŵƐ ?,^ĂƉƉĞĂƌƐƚŽďĞǁĞůů
ƚĂƌŐĞƚĞĚĂĐƌŽƐƐĂůů ?ƐĞǀĞƌŝƚǇ ? levels, providing for calibration of the scale by transforming raw scores 
into interval-level (Rasch-transformed) scores. 
Conclusions 
The validity and reliability of the HADS are confirmed in PsA and continues to be a useful 
psychological status instrument to use in PsA clinical studies. Raw scores can be Rasch-transformed 
into interval scores for use alongside other outcomes in parametric analyses. 
Table 1: Fit Statistics for the Anxiety and Depression Subscales in PsA (Baseline). 
Subscale Location SE Item Fit Residuals Chi-Square DF p-value 
Anxiety -0.120 0.021 -0.074 6.494 9 0.690 
Depression 0.120 0.022 0.356 9.384 9 0.403 
SE, Standard error; DF, Degrees of freedom, Non-significant p-value for Chi-Square suggests fit to Rasch model 
 Figure 1: Person-item Threshold Distribution Showing Targeting of the HADS (Baseline Data) 
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